Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 2:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 3,757 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Phase duration Clear all

Conditions: ER+ Breast Cancer
Interventions: Elacestrant; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: New Haven, Connecticut • Washington D.C., District of Columbia • Baltimore, Maryland + 4 more

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: naquotinib mesilate, Erlotinib, Gefitinib; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 25
States / cities: Beverly Hills, California • Fountain Valley, California • La Jolla, California + 21 more

Conditions: Chronic Pressure Ulcers
Interventions: PuraPly® Antimicrobial Wound Matrix, SOC for Pressure Ulcers; Device · Other
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Lake Success, New York • Mineola, New York

Conditions: Schizophrenia
Interventions: Lurasidone; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: B-Cell Chronic Lymphocytic Leukemia
Interventions: Lenalidomide, Chlorambucil; Drug
Lead sponsor: Celgene; Industry
Eligibility: 65 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 28
States / cities: Escondido, California • Whittier, California • New Britain, Connecticut + 25 more

Conditions: Cardiovascular Disease, End Stage Renal Disease, Atherosclerosis, Oxidative Stress
Interventions: Coenzyme Q10; Dietary Supplement
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions: Autologous cultured dermal and epidermal cells; Biological
Lead sponsor: Aderans Research Institute; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 6
States / cities: Atlanta, Georgia • Chevy Chase, Maryland • Boston, Massachusetts + 3 more

Conditions: Bone Loss, Implant Complication, Gingival Recession
Interventions: Definitive abutment; Device
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Fluid Retention, Sodium Retention, Heat Stress, Dehydration (Physiology), Renal Injury, Electrolyte and Fluid Balance Conditions
Interventions: PR Lotion - AMP Human Performance, Placebo Lotion, AminoVital - Rapid Recovery, Placebo Supplement; Other
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Speech Sound Disorder
Interventions: Visual-Acoustic Biofeedback Treatment, No Treatment; Behavioral · Other
Lead sponsor: Montclair State University; Other
Eligibility: 9 Years to 15 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Upper Montclair, New Jersey

Conditions: Central Nervous System Tumor, Pediatric, Chemotherapy-induced Nausea and Vomiting, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Real Acupressure Band, Placebo Acupressure Band; Procedure
Lead sponsor: University of South Florida; Other
Eligibility: 4 Years to 18 Years
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 24
States / cities: Long Beach, California • Los Angeles, California • Hartford, Connecticut + 20 more

Conditions: Brain Tumor, Recurrent
Interventions: Photofrin photodynamic therapy.; Drug
Lead sponsor: Harry T Whelan, MD; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Solid Tumors, Lung Cancer
Interventions: BKM120, Everolimus; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Neuroendocrine Cancer, Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Gastric Cancer
Interventions: thermochemotherapy, Cisplatin, Gemcitabine, Interferon-a; Other · Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Thrombin Inhibition
Interventions: AZD8165; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Diabetic Nephropathy
Interventions: SPP301; Drug
Lead sponsor: Speedel Pharma Ltd.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 2,364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Secondary Progressive Multiple Sclerosis
Interventions: Blood Draw, CSF collection by lumbar puncture (Optional); Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 13
States / cities: Berkeley, California • Los Angeles, California • Sacramento, California + 10 more

Conditions: Triple Negative Breast Cancer
Interventions: Paclitaxel, Carboplatin, Nivolumab, Cabiralizumab, Tumor biopsy, Bone marrow, Blood draw; Drug · Biological · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Secondary Immune Deficiency
Interventions: IgPro20; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 17
States / cities: Orange, California • Denver, Colorado • Coral Springs, Florida + 14 more

Conditions: Brain and Central Nervous System Tumors
Interventions: bleomycin, Ommaya reservoir, radiation therapy; Biological · Device · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 13
States / cities: Phoenix, Arizona • Lexington, Kentucky • Omaha, Nebraska + 10 more

Conditions: End Stage Renal Disease, Hemodialysis, Inflammatory Response, Cardiovascular Disease
Interventions: paricalcitol; Drug
Lead sponsor: Renal Research Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 3
States / cities: New York, New York

Conditions: Lymphedema, Breast Cancer
Interventions: Surgical Intervention, Conservative Complex Physical Decongestion Therapy; Procedure
Lead sponsor: University Hospital, Basel, Switzerland; Other
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2036
U.S. locations: 4
States / cities: New Haven, Connecticut • Boston, Massachusetts • Rochester, Minnesota + 1 more

Conditions: T-Cell Lymphoma
Interventions: Duvelisib, Peripheral blood draw; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Adenocarcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
Interventions: Biopsy, Biospecimen Collection, Probiotic, Therapeutic Conventional Surgery; Procedure · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Jacksonville, Florida

Search by objective public record fields.

Circulating Tumor DNA

A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations

PuraPly® AM Plus the Standard of Care to Standard of Care Alone for the Management of Stage II-IV Pressure Ulcers.

High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia

Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)

Safety and Tolerability of Coenzyme Q10 in Hemodialysis Patients

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002013)

The Effects of Dis/Reconnection of Implant Abutments on Peri-implant Bone Levels

The Effect of AMP Human Sodium Bicarbonate Lotion on Dehydrated Heat Stress

Visual Acoustic Biofeedback for RSE Via Telepractice

Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy

Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas

A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies

Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors

Oral AZD8165 After Single Oral Ascending Doses in Healthy Male Subjects

To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy

Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis

Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

Radiation Therapy Followed by Bleomycin in Treating Adult Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme

Immune Effects of Vitamin D in Hemodialysis Patients

The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema

Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas

Effects of Probiotics on the Gut Microbiome and Immune System in Operable Stage I-III Breast or Lung Cancer